Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2) ELISA, Neut, GICA Host: Human Monoclonal A1 unconjugated single-domain Antibody (sdAb) Recombinant Antibody
Catalog No. ABIN6953152
  • Target See all SARS-CoV-2 Spike S1 Antibodies
    SARS-CoV-2 Spike S1
    Antibody Type
    Recombinant Antibody
    Fragment
    single-domain Antibody (sdAb)
    Binding Specificity
    • 12
    • 3
    • 2
    • 2
    • 1
    RBD
    Reactivity
    • 40
    • 7
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2)
    Host
    • 15
    • 10
    • 5
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Clonality
    • 27
    • 9
    • 5
    Monoclonal
    Conjugate
    • 35
    • 3
    • 1
    • 1
    • 1
    This SARS-CoV-2 Spike S1 antibody is un-conjugated
    Application
    • 40
    • 9
    • 8
    • 7
    • 5
    • 5
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Neutralization (Neut), Colloidal Gold Immunochromatography Assay (GICA)
    Characteristics
    This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/mL IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
    VHH fusion with human IgG1 Fc
    Purification
    affinity-chromatography
    Immunogen
    Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa)
    Clone
    A1
    Isotype
    IgG1
    Featured
    Discover our best selling SARS-CoV-2 Spike S1 Primary Antibody
    Top Product
    Discover our top product SARS-CoV-2 Spike S1 Primary Antibody
  • Application Notes
    ELISA 1:10000-1:100000
    GICA 1:10000-1:40000
    Neutralising 1:100-1:10000
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    50 % Glycerol, 0.01M PBS, pH 7.4, 0.03 % Proclin 300
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C,-80 °C
    Storage Comment
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze
  • Target
    SARS-CoV-2 Spike S1
    Abstract
    SARS-CoV-2 Spike S1 Products
    Synonyms
    E2 antibody, Surface Glycoprotein antibody, S antibody
    Target Type
    Viral Protein
    Background
    Spike glycoprotein comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). For many coronavirus (CoVs), S is cleaved at the boundary between the S1 and S2 subunits, which remain non-covalently bound in the prefusion conformation. The distal S1 subunit comprises the receptor-binding domain(s) and contributes to stabilization of the prefusion state of the membrane-anchored S2 subunit that contains the fusion machinery. S is further cleaved by host proteases at the so-called S2' site located immediately upstream of the fusion peptide in all CoVs. This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes. However, different CoVs use distinct domains within the S1 subunit to recognize a variety of attachment and entry receptors, depending on the viral species. Endemic human coronaviruses OC43 and HKU1 attach via their S domain A to 5-N-acetyl-9-O-acetyl-sialosides found on glycoproteins and glycolipids at the host cell surface to enable entry into susceptible cells. MERS-CoV S uses domain A to recognize non-acetylated sialoside attachment receptors, which likely promote subsequent binding of domain B to the entry receptor, dipeptidyl-peptidase 4. SARS-CoV and several SARS-related coronaviruses (SARSr-CoV) interact directly with angiotensin-converting enzyme 2 (ACE2) via SB to enter target cells.
    Gene ID
    43740568
    UniProt
    P0DTC2
You are here:
Support